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Abstract 
Objectives  
Value of information (VOI) analyses can help policy-makers make informed decisions about whether to 
conduct and how to design future studies. Historically, a computationally expensive method to compute 
the Expected Value of Sample Information (EVSI) restricted the use of VOI to simple decision models 
and study designs. Recently, four EVSI approximation methods have made such analyses more feasible 
and accessible. We provide practical recommendations for analysts computing EVSI by evaluating these 
novel methods. 
Methods  
Members of the Collaborative Network for Value of Information (ConVOI) compared the inputs, analyst’s 
expertise and skills, and software required for four recently developed approximation methods. 
Information was also collected on the strengths and limitations of each approximation method. 
Results  
All four EVSI methods require a decision-analytic model’s probabilistic sensitivity analysis (PSA) output. 
One of the methods also requires the model to be re-run to obtain new PSA outputs for each EVSI 
estimation. To compute EVSI, analysts must be familiar with at least one of the following skills: advanced 
regression modeling, likelihood specification, and Bayesian modeling. All methods have different 
strengths and limitations, e.g., some methods handle evaluation of study designs with more outcomes 
more efficiently while others quantify uncertainty in EVSI estimates. All methods are programmed in the 
statistical language R and two of the methods provide online applications. 
Conclusion 
Our paper helps to inform the choice between four efficient EVSI estimation methods, enabling analysts 
to assess the methods’ strengths and limitations and select the most appropriate EVSI method given their 
situation and skills. 
 
Highlights 
 The Expected Value of Sample Information (EVSI) can be used to prioritize research and design 
future studies to reduce decision uncertainty for policy-makers. Four recently published methods 
have overcome the computational issues associated with EVSI analysis but practical guidance on 
using and distinguishing these methods is lacking.  
 Because the four methods use different approaches to estimate EVSI, requiring different expertise 
and skills, members of the Collaborative Network on Value of Information (ConVOI) reviewed 
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these four EVSI computation methods to understand their required skills and inputs. They also 
identified the strengths and limitations of these methods and provide step-by-step guides.  
 By comparing these methods, ConVOI provides practical guidance for analysts looking to 
compute EVSI and use it for study design. Analysts now have useful information to confidently 
select the most appropriate EVSI estimation method for their application and expertise.  
 
 
Introduction 
Decisions on which research studies to fund are intrinsically economic in nature; that is, public, private 
and third sector (research charity) funders have finite resources and their decisions bear an opportunity 
cost. Therefore, it is important to prioritise research studies that are expected to yield the greatest benefit 
for every dollar or euro spent. 
 
Typically, research priorities are set through consultation with experts, decision- or policy-makers and 
other key stakeholders (e.g., the James Lind Alliance [1]) [2]. Study outcomes are then selected for a 
number of reasons, such as ensuring timely collection of data. Most research designs focus on clinical 
outcomes and rarely consider economic implications. The sample size for most randomized controlled 
trials (RCTs) is determined using power calculations which explicitly manage type I and II errors for a 
statistical test of the selected primary outcome. However, this approach fails to take into account the 
opportunity cost of research: a large (and expensive) trial could be proposed while that knowledge could 
have minimal value to society. In contrast, Value of Information analysis (VOI) values an RCT and other 
types of research studies in terms of how much they reduce decision uncertainty (i.e., the probability of 
making a sub-optimal decision) about the best treatment for use in a population of interest. If a sub-
optimal decision is made, then potential health improvements are foregone. The probability of making the 
wrong decision is multiplied by the size of the loss incurred by that decision to generate the expected loss 
associated with making a sub-optimal decision [3]. New data are expected to reduce decision uncertainty, 
and so reduce the expected loss. The Expected Value of Sample Information (EVSI) measures the 
“expected reduction in expected loss" from a given research study. Scaled up to the relevant population 
this can be expressed in health terms of life years, or quality-adjusted life years (QALYs), or in monetary 
units [4, 5]. The difference between the EVSI and the cost of the research is the Expected Net Benefit of 
Sampling (ENBS). 
 
An increasing number of authorities and Health Technology Assessment (HTA) agencies acknowledge the 
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importance of VOI as part of a cost-effectiveness analysis and are recommending it [6-9]. Thus, EVSI 
methods will soon be required from analysts who conduct cost-effectiveness analyses for HTA agencies. 
Until recently, EVSI calculations were extremely computationally expensive, potentially taking weeks or 
months [10], as they required nested simulation methods [11]. Hence, most VOI analyses were restricted 
to computing the Expected Value of Perfect Information (EVPI) or the Expected Value of Partial Perfect 
Information (EVPPI). However, new algorithms and associated software [12-20] enable the efficient 
computation of EVSI for realistic decision models. 
 
While these methods have lowered the computational barriers to VOI analyses, they differ in their 
approach, requiring different expertise and skills. However, there is no structured comparison of the 
practical steps required to use them. Thus, it is challenging for analysts to determine which method is 
appropriate for their situation and expertise. Additionally, each method has different strengths and 
limitations that could make it more suitable for a given decision problem. The Collaborative Network for 
Value of Information (ConVOI) [21] is an international group of researchers with interests in the 
application and development of methods for VOI calculation. This manuscript provides practical guidance 
and good practice recommendations for computing EVSI using four recently developed approximation 
methods. For each method, we: 1) provide a step-by-step guide to its use, 2) compare the expertise and 
skills required to implement it, and 3) highlight its strengths and limitations. 
 
Four EVSI approximation methods 
This paper focuses on four recently developed estimation methods, developed by Strong, Oakley (13) 
(regression-based method [RB]), Menzies (14) (importance sampling method [IS]), Jalal and Alarid-
Escudero (16) building on work from Jalal, Goldhaber-Fiebert (15) (Gaussian approximation method 
[GA]), and Heath, Manolopoulou (17) (moment matching method [MM]). These calculation methods 
were selected as they place limited restrictions on the complexity of the underlying decision-analytic 
model and/or data collection exercise when calculating EVSI. The recommendations presented in this 
paper were developed and reviewed by ConVOI to aid analysts looking to compute EVSI. 
 
Inputs Required for Efficient EVSI Calculation 
The considered EVSI approximation methods have diverse requirements and make different assumptions. 
However, all require a decision-analytic model on which a probabilistic sensitivity analysis is conducted. 
The IS and MM methods also require calculation of the EVPPI for the parameter(s) to be evaluated and 
updated in the proposed study. If studies informing different parameters or groups of parameters are 
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considered, then EVPPI would need to be computed for each. The following section briefly outlines these 
requirements and assumptions. 
 
Decision-Analytic Model 
VOI requires an objective function that should be optimized to determine the best course of action [22]. 
Economic evaluations in health care typically define this in terms of net health or monetary benefit for 
each of 𝑇 interventions [23], which uses a “willingness-to-pay” threshold to put the health consequences 
on the same scale as the costs for the different interventions [23]. The function that computes this usually 
takes the form of a decision-analytic model. 
 
Decision-analytic models are mathematical models often used for cost-effectiveness analyses. They draw 
on set of inputs that we denote 𝜽. These inputs could include information on the prevalence of a disease, 
the effectiveness of treatments, background mortality, health-related utility weights and costs. The model 
can take a number of forms, foremost among them are decision trees, Markov models and microsimulation 
models [24]. Conceptually, the decision-analytic model maps a set of inputs to the output, net benefit 
(either in monetary or health units). Assuming risk neutrality, the intervention with the highest expected 
net benefit should be implemented in the wider population. 
 
Probabilistic Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA), sometimes known as probabilistic analysis or uncertainty analysis, 
is performed to propagate input parameter uncertainty to the model output under each decision alternative 
and thereby quantify decision uncertainty in a cost-effectiveness analysis [25]. PSA simultaneously varies 
all parameters for which there is meaningful uncertainty. Uncertainty in the model inputs is characterized 
using probability distributions, 𝑝(𝜽) [26]. 
 
PSA is often conducted using Monte Carlo methods where 𝑆 parameter sets are drawn from 𝑝(𝜽), for the 
whole set of model parameters 𝜽 = (𝜃1, … , 𝜃𝑃). The decision-analytic model is evaluated at all 𝜽𝒔, 𝑠 =
1, … , 𝑆 to estimate the costs and health outcomes of each of the 𝑇 strategies. This produces a distribution 
for the net monetary benefit for each strategy, which we denote NB𝑡
𝜽, for 𝑡 = 1, … , 𝑇. In non-linear 
models, PSA is required to generate the expected net monetary benefit of each treatment strategy, 
E𝜃[NB𝑡
𝜽]. PSA results can be presented in the form of a cost-effectiveness acceptability curve (CEAC), 
cost-effectiveness acceptability frontier (CEAF), expected loss curves (ELCs), and cost-effectiveness 
plane [3, 6]. Furthermore, PSA is key to determining the value of potential future research using VOI 
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methods. 
 
To compute EVSI, we require the PSA simulations of the model inputs 𝜽𝒔 and the corresponding 
simulations for the net monetary benefit NB𝑡
𝜽𝒔 for 𝑠 = 1, … , 𝑆 and 𝑡 = 1, … , 𝑇. These simulations should 
be saved in a matrix or spreadsheet form, often called a PSA dataset,1 where the columns contain first the 
input parameters and then the outputs from a decision-analytic model. Each row then contains the 
parameter sets drawn from their distributions, and their corresponding simulated results from a decision-
analytic model output. We have provided an example of the PSA simulations in Supplementary Materials. 
 
While PSA results are necessary for all the four efficient EVSI calculation methods, two of the methods 
(RB and GA) require the above mentioned PSA matrix from a traditional cost-effectiveness analysis while 
the other two (IS and MM) require an augmented PSA simulation matrix that is presented in the following 
section. 
 
Expected Value of Partial Perfect Information 
The EVPPI computes the value of eliminating all uncertainty about a subset of the model parameters [27-
29]. Specifically, the model parameters are split into two subsets 𝜽 = (𝜙, 𝜓), where we propose to gather 
further information about the model parameters 𝜙. Typically, a proposed study does not collect 
information about all the underlying parameters in a decision-analytic model and therefore, 𝜓 indicates 
the parameters that will not be directly informed by the proposed data collection. 
Mathematically, the EVPPI for the parameters 𝜙 is defined as  
 
 EVPPI =  E𝜙 [max
𝑡
 E𝜓|𝜙[NB𝑡
𝜽]] − max
𝑡
 E𝜃[NB𝑡
𝜽],                    (1) 
 
where the inner expectation in the first term of equation (1) calculates the net monetary benefit for each 
intervention conditional on 𝜙. The second term calculates the value of the decision made with current 
information, i.e., the expected net benefit of the treatment with the highest expected net benefit. 
 
                                                     
1The word “dataset” is not used in the traditional sense; here, the PSA dataset simply contains simulated values from distributions representing the 
uncertainty in the parameter estimates. 
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The PSA outcomes are simulated using probability distributions for 𝜙 and the EVPPI is estimated by 
computing the net monetary benefit for each intervention conditional 𝜙 = 𝜙𝑠 for 𝑠 = 1, … , 𝑆. Several 
approximation methods are available to estimate the conditional net monetary benefit for each value 𝜙𝑠 
[27, 30-34] and have been formally assessed in [28] and [29]. Software is also available to perform these 
calculations [35-37]. The MM and IS methods require a PSA simulation matrix with 𝑇 additional 
columns that contain Monte Carlo estimates of the expected net benefits E𝜓|𝜙[NB𝑡
𝜽], conditional on 𝜙𝑠 
for 𝑠 = 1, … , 𝑆, but averaged over the uncertain values of 𝜓. We denote these simulations 𝜂𝑡
𝑠. 
 
EVSI Methods 
EVSI for a proposed research strategy that collects additional data, denoted 𝑿, is defined as  
  
 EVSI =  𝐸𝑿 [max
𝑡
 E𝜽|𝑿[NB𝑡
𝜽]] − max
𝑡
 E𝜽[NB𝑡
𝜽].                    (2) 
   
In this setup, 𝑿 are observable, but not yet observed — and possibly never will be. At this stage, we 
consider the possibility of collecting data in the future and we compute EVSI to determine whether we 
should defer making a decision on the optimal intervention, among the 𝑇 possible options, and instead 
invest money and time collecting 𝑿. 
 
In line with a full Bayesian approach (which underpins the ideas behind the VoI analysis), the distribution 
of 𝑿 is defined by 𝑝(𝑿, 𝜽) = 𝑝(𝜽)𝑝(𝑿|𝜽) where 𝑝(𝜽) is the marginal distribution of 𝜽 and 𝑝(𝑿|𝜽) is 
the sampling distribution of the data. In a full Bayesian setting, 𝑝(𝜽) is a “prior” distribution — in the 
sense that it represents the current level of uncertainty on the model parameters, before observing the new 
data 𝑿. In reality, this distribution is defined by the PSA procedure and can represent the result of a 
Bayesian update given observed data that is used to construct the current economic model. 
 
We note that 𝑿 will give information on the subset of model parameters 𝜙, where 𝜙 could be the whole 
set 𝜽. By definition, this means that 𝜓 and 𝑿 are independent given 𝜙 and that 𝑝(𝑿|𝜽) = 𝑝(𝑿|𝜙). 
 
The second term of equation (2) can be estimated from the initial PSA. To obtain simulations for 𝑿, we 
simulate potential study outcomes, 𝑿𝒔, 𝑠 = 1, … , 𝑆, for each row of the PSA dataset, i.e., we generate a 
single sample from 𝑝(𝑿|𝜽𝒔) for 𝑠 = 1, … , 𝑆. Traditionally, EVSI has been computationally demanding 
and methodologically challenging because a large number of simulations are needed to estimate the 
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posterior mean of the net benefit for each 𝑿𝒔. This requires a Bayesian model for the distribution of the 
data and the parameters, where the posterior mean is given by  
  
𝜇𝑡(𝑿𝒔) = E𝜽|𝑿𝒔[NB𝑡
𝜽].                    (3) 
    
The EVSI approximation methods in this paper estimate 𝜇𝑡(𝑿) with a reduced computational burden. For 
computational simplicity and stability, VOI calculations should be undertaken using incremental net 
benefit defined, without loss of generality, as  
 
INB𝑡
𝜽 =  NB𝑡∗
𝜽 −  NB𝑡
𝜽, 
 
for 𝑡 = 2, … , 𝑇. We could also use the opportunity loss, defined as the incremental net benefit of all 
treatments from the optimal strategy 𝑡∗. By estimating the posterior mean of the incremental net benefit, 
we only need to add 𝑇 − 1 columns containing the posterior mean conditional on 𝑿𝒔 to our PSA dataset. 
Once these simulations, denoted 𝜇𝑡(𝑿𝒔), are available, the EVSI can be estimated by  
 
1
𝑆
∑
𝑆
𝑠=1
max
𝑡
{𝜇𝑡(𝑿𝒔)} − max
𝑡
{
1
𝑆
∑
𝑆
𝑠=1
𝜇𝑡(𝑿𝒔)},                    (4) 
 
where 𝜇1(𝑿𝒔) = 0 for all 𝑠 = 1, … , 𝑆. 
 
Expertise Required for EVSI Calculation 
We have identified three skills that the analyst may require to compute EVSI using the approximation 
methods reviewed in this manuscript. None of the methods require all three skills but each method 
requires the mastery of at least one of the skills presented. Table 1 summarises the required skills and 
inputs for each method. 
 
Regression Methods 
Regression methods that model the relationship between a set of predictors and an outcome of interest are 
required for both the RB and GA methods. Both methods use regression metamodeling to model the 
incremental net benefit as a function of model inputs or quantities related to model inputs. The two 
methods differ as they require alternative covariates. 
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Both of these EVSI methods model relatively complex relationships using models that require little 
information about the functional relationship between the independent and dependent variables. To 
account for potential nonlinear relationships between these variables, flexible regression methods 
characterized using Generalized Additive Models (GAMs) [38] are the predominant regression methods 
for EVSI calculation. Standard software is available to fit GAMs [39-41], but the EVSI estimate can be 
affected by the structure of the GAM model and, thus, an understanding of these models is required. 
Gaussian Processes [42] have also been suggested for more complex problems [13], so knowledge of 
these methods may also be required. 
 
If regression methods are used to estimate EVSI, it is important to assess whether the regression model 
has correctly captured the relationship between the independent and dependent variables [13]. Regression 
methods assume that the residual error is uncorrelated with the fitted values from the regression, has zero 
mean and trivial covariance structure. These assumptions can be confirmed by observing no groups, 
systematic features, or outliers in the plot of the residuals against the fitted values [43]. 
 
Specification of data generating distribution 
EVSI computes the expected value of collecting information in a future research study. The future 
research study would collect a potential data set, 𝑿, with 𝑁𝒪 different clinical, health or economic 
outcomes from 𝑁 participants. For example, a clinical trial would collect the primary and secondary 
outcomes from each participant. 
 
All EVSI computation methods require the simulation of potential data sets (the GA method requires 
study data simulation to compute the effective sample sizes of the priors of the 𝜙 only if these cannot be 
estimated directly, c.f. Bayesian Updating). As outlined above, this is achieved by specifying the assumed 
data generating distribution 𝑝(𝑿|𝜙). Thus, analysts must have knowledge of probability distributions. 
 
For the RB method, the simulated data sets 𝑿𝒔 for 𝑠 = 1, … , 𝑆 must be summarized to reflect how the 
data would be analyzed following the trial. This requires expertise in standard methods for the statistical 
analysis of study results, for example, maximum likelihood procedures. A variation of the GA method can 
be also be applied if a summary statistic is available. 
 
For the IS method, the analytic likelihood for 𝑿 must be specified and coded as a function. Likelihood is 
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used in its proper statistical meaning and, therefore, this specification requires statistical expertise. 
Typically, this likelihood specification will require an analyst who has knowledge of statistical theory, 
function development and coding. 
 
Bayesian Updating 
Bayesian methods are a statistical paradigm in which conclusions are formally updated as evidence 
accumulates [44]. A full Bayesian model consists of probability distributions specified for the model 
inputs 𝑝(𝜽), the prior distribution defined using the PSA distributions, and the sampling distribution for 
the proposed data collection. Based on these distributions, Bayesian methods update the distribution of the 
parameters conditional on the data 𝑿 to produce a posterior distribution. In practice, this is undertaken 
using specialized software such as BUGS [45], JAGS [46] or Stan [47]. The MM and, in some cases, GA 
methods are explicitly based on Bayesian analysis, which requires expertise in these programs and in the 
specification of Bayesian models. This is advantageous if the final trial analysis will be performed 
according to Bayesian principles as the statistical analysis plan has been developed as part of the design 
process. 
 
Additionally, the GA method is based on the prior effective sample size [48]. The prior effective sample 
size, denoted 𝑛0, is the number of participants that would need to be studied to obtain the level of 
information in the prior. In some Bayesian models, typically based on conjugate prior-likelihood pairs, the 
prior effective sample size can be estimated directly from the parameters of the distributions [48]. If this is 
not possible, then Jalal and Alarid-Escudero (16) present two algorithms to compute the prior effective 
sample size (see the Supplementary Materials). The first of these is based on summary statistics and the 
second on a full Bayesian analysis. 
 
Table 1. The skills and inputs required to compute EVSI with the regression-based, importance sampling, 
Gaussian approximation and moment matching methods 
# Requirements  RB IS GA MM 
 Inputs      
1 Decision-analytic model      
2 Probabilistic sensitivity analysis      
3 Simulations of the expected net benefit  
conditional on 𝜙 (required to compute EVPPI)  
    
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 Skills      
1 Regression methods      
2 Specification of likelihoods    *  
3 Bayesian updating    *  
GA, Gaussian approximation method; IS, importance sampling method; MM, moment matching method; RB, 
regression-based method;  indicates that the skill/input is required; * indicates that the skill/input may be required. 
   
Calculating EVSI 
To highlight how these skills and inputs are used to compute EVSI, we have presented step-by-step guides 
to each of the four methods considered. These algorithms are provided in Boxes 1-4. 
 
Box 1. Step-by-step guide for regression-based method 
 
INB, incremental net benefit; PSA, probabilitic sensitivity analysis; θ, set of inputs in a decision-analytic model; 
p(θ), probability distributions to characterize uncertainty in the model inputs; S, number of parameter sets that are 
drawn from p(θ) in PSA; T, number of considered interventions; θ=(φ,ψ), φ are model parameters for which we are 
aiming to collect further information and ψ are parameters that will not be directly informed by the proposed data 
collection; X, new data proposed to be collected; μ, posterior mean; W(X), a summary measure for the data. 
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Box 2. Step-by-step guide for importance sampling method 
 
INB, incremental net benefit; EVPPI, Expected Value of Partial Perfect Information; PSA, probabilitic sensitivity 
analysis; θ, set of inputs in a decision-analytic model; p(θ), probability distributions to characterize uncertainty in the 
model inputs; S, number of parameter sets that are drawn from p(θ) in PSA; T, number of considered interventions; 
θ=(φ,ψ) φ are model parameters for which we are aiming to collect further information and ψ are parameters that will 
not be directly informed by the proposed data collection; X, new data proposed to be collected; μ, posterior mean; η, 
PSA simulations used to compute EVPPI. 
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Box 3. Step-by-step guide for Gaussian approximation method 
 
INB, incremental net benefit; PSA, probabilitic sensitivity analysis; θ, set of inputs in a decision-analytic model; S, 
number of parameter sets that are drawn from p(θ) in PSA; T, number of considered interventions; θ=(φ,ψ) φ are 
model parameters for which we are aiming to collect further information and ψ are parameters that will not be 
directly informed by the proposed data collection; X, new data proposed to be collected; μ, posterior mean. 
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Box 4. Step-by-step guide for moment matching method 
 
INB, incremental net benefit; EVPPI, Expected Value of Partial Perfect Information; EVSI, Expected Value of 
Sample Information; PSA, probabilitic sensitivity analysis; θ, set of inputs in a decision-analytic model; p(θ), 
probability distributions to characterize uncertainty in the model inputs; S, number of parameter sets that are drawn 
from p(θ) in PSA; T, number of considered interventions; θ=(φ,ψ) φ are model parameters for which we are aiming 
to collect further information and ψ are parameters that will not be directly informed by the proposed data collection; 
X, new data proposed to be collected; μ, posterior mean; η, PSA simulations used to compute EVPPI; Q, number of 
times PSA is performed. 
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Strengths and Limitations 
As each method is different, the most suitable method for EVSI calculation will depend on the decision-
analytic model, the sampling distribution for the data, the expertise of the analyst and the amount of 
computation time available. The following section highlights the strengths and limitations of these 
methods to help analysts select the most appropriate method. A summary of these strengths and 
limitations is presented in Table 2. 
 
Regression-Based Method 
Strengths 
The decision-analytic model does not need to be rerun to produce EVSI estimates, so EVSI can be 
computed by an analyst with access to the PSA results only. Standard statistical software includes 
procedures to fit flexible regression models, particularly GAM regression, making this method relatively 
simple to implement once the summary statistics 𝑊(𝑿𝒔) are available. Furthermore, EVSI estimates 
across different sample sizes for the future data are obtained at a constant computational cost. Finally, if 
the model is judged to fit well, an estimate of the uncertainty in the EVSI estimate can be obtained using 
an algorithm developed by Strong, Oakley (13). 
 
An online application [36] was developed to compute the EVPPI, using the regression-based method [31]. 
This tool, called Sheffield Accelerated Value of Information (SAVI), fits a regression model between the 
INB𝑡
𝜽𝒔 and the parameters of interest 𝜙. Due to the similarity between the EVPPI and EVSI calculation 
methods, SAVI can be used to compute EVSI, once the future data sets have been summarized 𝑊(𝑿𝒔), 
𝑠 = 1, … , 𝑆. This is achieved by augmenting the PSA matrix with (a) column(s) containing the data 
summaries. This must be saved and uploaded into SAVI and EVSI is then equal to the “EVPPI” calculated 
for the column(s) containing the data summary. 
 
Limitations 
For complex studies where the number of collected outcomes 𝑁𝒪 is greater than five or six, it can be 
challenging to fit a sufficiently accurate regression model. The simulated study data must also be correctly 
summarised using 𝑊(𝑿) to obtain accurate EVSI estimates. This can be challenging and time-consuming 
in more complex studies. The relationship between the incremental net benefit and 𝑊(𝑿) must also be 
well-approximated by the regression model to ensure accurate EVSI estimation. 
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Importance Sampling Method  
Strengths 
This method only requires the PSA results to compute the EVSI (i.e., access to the original decision-
analytic model is not necessary). Furthermore, the IS method can be used irrespective of the number of 
study outcomes 𝑁𝒪 with similar complexity, once the likelihood function for the potential data to be 
collected has been defined. 
 
Limitations 
The accuracy of the EVSI estimation relies heavily on the appropriate specification of the analytic 
likelihood and the accurate estimation of the EVPPI. Because the most efficient EVPPI estimation 
methods are based on regression methods [29, 31], the analyst must be confident assessing the accuracy of 
regression models before proceeding with EVSI estimation. Furthermore, the IS method can have 
computational issues for large sample sizes of the future data as the likelihood tends to 0 with increasing 
sample size, leading to inaccurate EVSI estimation [10]. Finally, uncertainty in the EVSI estimation 
procedure cannot be estimated using this method. 
 
Gaussian Approximation Method  
Strengths 
Estimation of EVSI with this method does not require to rerun the decision-analytic model; thus, access to 
PSA results is sufficient. This method estimates EVSI using flexible non-parametric (typically GAM) 
linear regression models. Although GA method requires an estimate of the prior effective sample size 𝑛0 
for the proposed data collection, 𝑛0 can be estimated directly from previous studies. Furthermore, this 
method estimates EVSI across different sample sizes of the proposed data collection exercise at minimal 
computational cost, once the prior effective sample size has been estimated. Thus, the optimal sample size 
for proposed data collection can be obtained cheaply. Finally, the method can estimate the uncertainty in 
the EVSI estimation procedure using the same approach as in [13] based on [49]. 
 
An online repository is available for the GA method (https://zenodo.org/record/3263876), which contains 
a function that estimates the fitted values 𝜇𝑡(𝑿𝒔) from a GAM regression model [38] and estimates of 𝑛0
𝑝
 
for 𝑝 = 1, … , 𝑃. Thus, implementation for this method can be automated if estimates for the effective 
sample size are available for each parameter and if a GAM regression model accurately captures the 
relationship between the incremental net benefit and the parameters of interest. 
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Limitations 
This estimation method can lead to inaccurate EVSI estimation if the prior effective sample size is small. 
Relatively intensive simulation methods may also be required to estimate the prior effective sample size if 
it cannot be obtained directly. The GA method also relies on a regression model, which may perform 
poorly if the regression model does not capture the relationship between the net monetary benefit and the 
parameters 𝜙. Moreover, if the number of collected outcomes 𝑁𝒪 is over five or six, flexible GAM 
regression methods become challenging [31]. Although the analyst can use linear regression model 
instead, this model may not be sufficiently capture the relationship, leading to inaccurate EVSI estimates. 
 
Moment Matching Method 
Strengths 
This method uses the same nested simulation structure as the gold standard nested Monte Carlo methods. 
This means that if an analyst has already developed the nested Monte Carlo method for EVSI estimation, 
it can be easily adapted for this method. Furthermore, this method has been extended [19] to estimate 
EVSI for multiple alternative sample sizes with a fixed additional computational cost. This extended 
method also provides a measure of uncertainty around the final EVSI estimate. The MM method can 
estimate EVSI irrespective of 𝑁𝒪 the number of outcomes considered. 
 
The EVSI package in R has been developed to implement the MM method based on a Bayesian 
decision-analytic model. The manual is available [50] and the EVSI package can be installed in R using 
the command: devtools::install_github("annaheath/EVSI")  
 
Limitations 
The MM method requires simulated study data and relies on performing a PSA 𝑄 times, with 30 < 𝑄 <
50. Thus, the decision-analytic model must be rerun a significant number of times. Therefore, in 
computationally expensive decision-analytic models, such as microsimulation models, this method 
requires significant computational power. Next, if the original PSA simulation size is small, this method is 
inaccurate as it is based on an estimate of the variance of NB𝑡
𝜽𝒔, which must be sufficiently accurate. The 
MM method can also lead to inaccurate EVSI estimates when the sample size of the proposed study is less 
than 10. Finally, this method requires an accurate estimate of EVPPI and is more accurate for studies that 
will have significant impact on the underlying uncertainty in the decision-analytic model, i.e., the EVPPI 
of 𝜙 needs to be high compared to the value of reducing all model uncertainty (i.e., EVPI), ideally greater 
than 40%. 
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Table 2. Selected strengths and limitations of the four EVSI approximation methods 
# Characteristics  RB IS GA MM 
 Strengths      
1 Estimates EVSI for complex studies collecting  
a large number of outcomes  
    
2 Only requires the PSA results      
3 Uses non-parametric (typically GAM) regression      
4 Estimates EVSI for different study sizes with same 
computational cost  
    
5 Quantifies uncertainty in estimate      
 Limitations      
1 Requires simulated study data    *  
2 Requires accurate EVPPI estimation      
3 Can be computationally challenging to estimate EVSI  
for proposed studies with a large sample size  
    
4 Requires simulated study data to be summarized in  
a low dimensional statistic  
    
5 Struggles if proposed study has more than 5 outcomes      
6 May estimate inaccurate EVSI if the proposed study  
has small prior effective sample size  
    
7 May estimate inaccurate EVSI if the proposed study  
has small sample size  
    
GA, Gaussian approximation method, IS, importance sampling method, MM, moment matching method; RB, 
regression-based method;  indicates that the characteristic is required for the given method; * indicates that the 
characteristic may be required for the given method. 
 
Real-World Examples 
To aid the implementation of the reviewed EVSI methods, we have created a comprehensive GitHub 
repository that presents the code used to compute EVSI in the original publications, available at 
https://github.com/convoigroup. This repository also contains a suite of practical examples of EVSI 
computation that demonstrate EVSI calculations across several real-world examples using common 
decision-analytic model structures, such as Markov models. We provide both an example that was 
previously published in the literature [51] and hypothetical examples. These examples are all developed in 
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the statistical computing language R. Thus, our GitHub repository demonstrates how the reviewed 
methods can be used in practice and will help analysts to implement VOI methods in their own work.  
 
Presenting EVSI results 
Once EVSI results are available, the EVSI package in R contains several graphical displays to present 
EVSI and related quantities to practitioners and stakeholders. Results of an EVSI analysis can be loaded 
into the EVSI package, irrespective of the computation method used. These graphics can then be displayed 
in R directly or explored using a dynamic graphical display launched from within R. For analysts 
unfamiliar with R, EVSI results can be loaded into an online interface and these graphics can be explored 
online at https://egon.stats.ucl.ac.uk/projects/EVSI/Test/. The optimal sample size estimated using VOI 
methods can also be presented in form of a curve of optimal sample size (COSS) [52]. 
 
Conclusion 
VOI analysis has the potential to guide policy-makers in the prioritization and design of future research 
studies, thereby improving decision-making. Increasingly, HTA agencies are acknowledging this potential 
and are recommending VOI analyses to determine whether/what potential future research is needed. In 
this study, members of ConVOI have provided a practical guide and good practice recommendations to 
facilitate the implementation of these methods. Our recommendations outline the inputs, analyst skills, 
and software required to use each of the EVSI approximation methods. We have also highlighted the 
strengths and limitations of each method. These recommendations are supported by a recent review that 
compared properties of these four recently developed, efficient computation methods across three 
decision-analytic models [10]. 
 
An accompanying GitHub repository includes R code demonstrating all four EVSI methods in real-world 
examples. Thus, this guide helps analysts choose the method that is the most suitable for their application 
and skills, and our code repository provides practical support to aid the implementation of these methods. 
This increases the feasibility and accessibility of the EVSI methods as they become an important and 
required tool. 
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1 PSA Matrix 
We provide an example of a PSA dataset in Table S1 and an example of an augmented dataset in Table S2. 
 
Table S1. An example of a PSA dataset from a traditional cost-effectiveness analysis 
 
QALY, quality-adjusted life years; θ, set of inputs in a decision-analytic model; S, number of parameter sets that are drawn from p(θ) in PSA; T, number of 
considered interventions; θ=(φ,ψ), φ are model parameters for which we are aiming to collect further information and ψ are parameters that will not be directly 
27 
 
informed by the proposed data collection; p.dr.t, input parameter probability of distant recurrence for strategy t=1,…,T; hr.dr.t, input parameter hazard ratio of 
distant recurrence for strategy t=1,…,T; p.tox.t, input parameter probability of treatment toxicity for strategy t=1,…,T; u.ndr, input parameter utility weigth for 
non distant recurrence health state; u.dr, input parameter utility weigth for distant recurrence health state; u.d.tox, input parameter utility weight decrement due to 
treatment toxicity; c.dr, input parameter cost of distant recurrence health state; c.tox, input parameter cost of treatment toxicity; qaly.t, model outcome QALYs for 
strategy t=1,…,T; cost.t, model outcome costs for strategy t=1,…,T.    
 
Table S2. An example of an augmented PSA dataset 
 
θ, set of inputs in a decision-analytic model; S, number of parameter sets that are drawn from p(θ) in PSA; T, number of considered interventions; θ=(φ,ψ), φ are 
model parameters for which we are aiming to collect further information and ψ are parameters that will not be directly informed by the proposed data collection; 
nmb.t, net monetary benefit for strategy t=1,…,T ; evppi.t, expected value of partial perfect information for strategy t=1,…,T.
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2 Prior Effective Sample Size Algorithms 
This section proposes three alternative methods for calculating the prior effective sample size. The 
effective sample size 𝑛0 is the number of patients that would have to provide data to generate the 
“amount” of information in the prior.  
2.1 Direct Estimation 
In some settings, 𝑛0 can be found from the parameters prior distribution. For example, 𝑛0 for a beta prior 
𝐵𝑒𝑡𝑎(𝑎, 𝑏) coupled with a binomial likelihood 𝑥 ∼ 𝐵𝑖𝑛(𝑛, 𝑝) is equal to 𝑎 + 𝑏. This comes from 
conjugacy as the posterior distribution is 𝐵𝑒𝑡𝑎(𝑎 + 𝑥, 𝑏 + (𝑛 − 𝑥)). This is the case for specific 
conjugate pairs listed in Table S3. 
 
Table S3. Identifying 𝑛0 from parameters’ prior distribution 
Prior Likelihood Effective Sample Size 
𝐵𝑒𝑡𝑎(𝑎, 𝑏) Binomial 𝑎 + 𝑏 
𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏) Exponential 𝑎 
𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏) Poisson 
1
𝑏
 
𝑁𝑜𝑟𝑚𝑎𝑙(𝑎, 𝑏) Mean in Normal with known variance 𝜎2 
𝜎2
𝑏
 
𝐼𝑛𝑣𝑒𝑟𝑠𝑒𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏) Variance in Normal with known mean 𝑎 
 
2.2 Calculating a Summary Statistic 
This method uses a Gaussian approximation to compute 𝑛0 based on a summary statistic 𝑊(𝑿𝑠). 
Specifically, the data must be simulated and summarised following the method described in the 
Specification of data generating distribution section. We can assume that this summary statistic is 
approximately Gaussian and that the prior for the parameter of interest is also approximately Gaussian. In 
this setting,  
    𝑉𝑎𝑟 (𝑊(𝐗𝑠)) =
𝜎2
𝑛
+
𝜎2
𝑛0
, 
where 𝜎2 is an unknown variance. However, we know that  𝑉𝑎𝑟 (𝜙) =
 𝑉𝑎𝑟 (𝐗)
𝑛0
 so we can solve for 𝑛0;   
          ?̂?0 = 𝑛 (
 𝑉𝑎𝑟 (𝑊(𝐗𝑠))
 𝑉𝑎𝑟 (𝜙)
− 1), 
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where  𝑉𝑎𝑟 (𝑊(𝐗𝑠)) and  𝑉𝑎𝑟 (𝜙) are the variances of the summary statistic and the prior, respectively. 
Therefore, if we have calculated the summary statistic by summarising a dataset of size 𝑛, we can 
compute the 𝑛0 using this formula. 
However, in these cases, we need to compute a summary statistic that is “on the same scale” as 
the parameter. For example, the prior in a beta-binomial is typically a probability between zero and 1, 
while the binomial likelihood is generally the distribution of the number of successes. Therefore, the 
summary statistic must convert the data into the proportion of successes, which can be easily achieved by 
dividing the number of successes by the total sample. In some setting this may be non-trivial. For these 
settings, we propose an indirect Markov chain Monte Carlo (MCMC) approach. 
2.3 Using MCMC 
 In this case, we calculate the posterior mean for the parameter of interest 𝝓 for each simulated 
value of 𝑿𝑠, denoted 𝜇𝛟
𝑠 . The prior effective sample size can then be estimated from the variance of 𝜇𝛟
𝑠  
using the following formula:  
      ?̂?0 = 𝑛 (
 𝑉𝑎𝑟 (𝜙)
 𝑉𝑎𝑟 (𝜇𝛟)
− 1). 
More information about calculating 𝑛0 can be found in [1] alongside code to estimate 𝑛0 within R. 
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